As it is, Dendreon must take the study to its full term, and those results won't be due until 2009. Back story here. In the meantime, three things have happened: The stock has gone up -- so lots of people clearly think Dendreon is going to …
09/21 Neuralstem and Aradigm spike, equity offerings on the way? 09/20 TiGenix stock price target raised to $30 from $22 at Canaccord Genuity #news 09/19 Briefing actions (19 sept) - Solvay, Proximus, Umicore, Ageas, Telenet, Ontex.. …
After extremely weak performance in early 2014, the biotechnology industry understandably dropped off the radar of most investors. For those who haven’t been watching, the industry has quietly been making a comeback. For risk-tolerant …
Dendreon's stock price took a hit, as investors tried to second-guess which way the winds were blowing at the agency. But as the previous panel had voted for approval with clinical data that fell short of statistical significance, it seemed …
Providing that sometimes requires additional lengthy and expensive clinical trials. Although the near-term impact on Dendreon’s stock was severe — its shares plunged by 60 percent on the news — chances are good that Provenge or …
The Dendreon Corporation said yesterday that it had agreed to buy Corvas International Inc. for $72.9 million in stock to expand its experimental drug portfolio and add cash to its balance sheet. The purchase would add early-stage cancer …
On Tuesday, results of the new study boosted Dendreon stock by $9.69, closing at $16.99 ... The cells are mixed with a protein found on most prostate cancer cells to help activate the immune system. The resulting "vaccine" is given back …
Shares in Dendreon Corp have gone through the roof after the US firm presented highly positive late-stage data on its investigational prostate cancer vaccine Provenge. The company says that its Phase III IMPACT study of Provenge …
Dendreon is going to webcast the meeting ... Today they're hitting another new high of more than 30 bucks after Leerink Swann started covering the stock with the equivalent of a "Buy" rating. Analyst Howard Liang is putting a $40 12-month …
Prostate cancer drug developer Dendreon is seeking Chapter ... to resign for personal reasons. Shares of Dendreon shed most of their value Monday before markets opened, sinking 67 cents to 27 cents. The stock had slipped below $1 …